Our Business

Endo International plc

Headquartered in Dublin, Ireland

$4.0 Billion

in revenue in 2016


from previous year

U.S. Generic Pharmaceuticals


Headquartered in Chestnut Ridge, New York

4th largest U.S. generics company based on market share. Develops, licenses, manufactures, markets and distributes safe, innovative and cost-effective pharmaceuticals with a focus on first-to-file or first-to-market opportunities and high-barrier-to-entry products that are difficult to formulate, difficult to manufacture, or that face complex legal and regulatory challenges. The generics R&D pipeline consists of over 200 products including approximately 120 ANDAs pending with the FDA.

$2.6 Billion in revenue in 2016

Segment Milestones

  • Completed generics restructuring and rationalized the generics portfolio and manufacturing network driving greater efficiency
  • Launched approximately 20 new products including 2 key first-to-file products – quetiapine ER and ezetimibe
  • Filed 27 regulatory submissions

Key Product Lines


U.S. Branded Pharmaceuticals

Headquartered in Malvern, Pennsylvania

Focused on developing and marketing high-value, quality branded pharmaceutical products for patients in need. Endo Pharmaceuticals’ portfolio includes products for urology, men’s health, orthopedics, endocrinology and hematology.

$1.2 Billion in revenue in 2016

Segment Milestones

  • Increased demand for XIAFLEX® in Peyronie’s Disease and Dupuytren’s Contracture with sales growing 20% in 2016
  • Highly statistically significant Phase 2b data for XIAFLEX® in Cellulite
  • Enhanced focus on our Specialty Branded Pharmaceuticals after returning BELBUCA™ to our partner and exiting promotion of pain medicines

International Pharmaceuticals


Our International Pharmaceuticals businesses included: Paladin Labs, headquartered in Montreal, Canada; SOMAR, headquartered in Mexico City, Mexico; and Litha, headquartered in Midrand, South Africa.

$279 Million in revenue in 2016

Segment Milestones

  • Paladin Labs secured Canadian rights to XIAFLEX® and launched the product in the fourth-quarter 2016
  • Paladin Labs launched NUCYNTA® in the fourth-quarter 2016
  • Initiated a sales process for Litha and related Sub-Sahara African business assets. The sale was announced in February 2017 and expected to close in the second-quarter 2017